As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical …

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in …

Feb 5, 2025 · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors …

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future …

Here you will find everything related to our obesity treatments, information on how to use your medication devices, as well as information about our clinical trials, and our treatment …

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and …

Jan 27, 2025 · Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within …

Novo Nordisk® is committed to discovering, developing, and delivering resources and tools to help enhance weight-loss discussion and motivate healthy changes.

Feb 3, 2025 · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. The phase 1b/2a results show the potential of amycretin, a unimolecular …

6 days ago · With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over …